A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C +Pharmacogenetics Blood Sample Amendment 01 - Site Specific (version 1.0, dated 14-May-12).

Trial Profile

A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C +Pharmacogenetics Blood Sample Amendment 01 - Site Specific (version 1.0, dated 14-May-12).

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Daclatasvir (Primary) ; Simeprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
    • 04 Mar 2014 Status changed from active, no longer recruiting to completed according to a Medivir AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top